Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years.

Conclusion No clinically significant differences were seen in overall QOL measured by the SF-36 summary measures and MENQOL between the letrozole and placebo groups. The data indicate that continuation of aromatase inhibitor therapy after 5 years of prior treatment in the trial population was not associated with a deterioration of overall QOL. PMID: 29328860 [PubMed - as supplied by publisher]
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: J Clin Oncol Source Type: research

Related Links:

 Back in February, MD+DI got the low down from an obstetrics and gynecologist specialist in Lubbock, TX on a new vaginal rejuvenation device that her patients have been raving about.  Now it seems the manufacturer of that particular device, along with other companies selling laser- or energy-based devices for vaginal rejuvenation failed to get FDA's blessing. "We've recently become aware of a growing number of manufacturers marketing 'vaginal rejuvenation' devices to women and claiming these procedures will treat conditions and symptoms related to menopause, urinary incontinence, or...
Source: MDDI - Category: Medical Devices Authors: Tags: Regulatory and Compliance Source Type: news
Authors: Yuan X, Yi F, Hou C, Lee H, Zhong X, Tao P, Li H, Xu Z, Li J Abstract BACKGROUND: The association between induced abortion and birth control methods (including oral contraceptives and intrauterine devices) and breast cancer may vary among countries, due to the different usage and frequency of birth control methods and induced abortion among countries. A better understanding of this association may help in determining safer birth control methods for Chinese women. METHODS: A case-control study was conducted with a total of 794 cases and 805 controls. Standardized questionnaires were used to collect info...
Source: Journal of Epidemiology - Category: Epidemiology Tags: J Epidemiol Source Type: research
CONCLUSIONS: In this long-term follow-up study, taking hormones during menopause was not associated with overall mortality among middle-aged women. Investigating cause-specific mortality revealed significant albeit weak associations differential according to both causes of death and over time underlining the importance of carefully considering individual risks and duration of treatment when making decisions on hormone therapy. This article is protected by copyright. All rights reserved. PMID: 30106241 [PubMed - as supplied by publisher]
Source: BJOG : An International Journal of Obstetrics and Gynaecology - Category: OBGYN Authors: Tags: BJOG Source Type: research
Condition:   Breast Cancer Female Interventions:   Behavioral: Starting the Conversation Video;   Behavioral: Sexual and Menopausal Health Resources Sponsors:   Fox Chase Cancer Center;   American Cancer Society, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusions: History of alendronate use is associated with a lower likelihood of bone metastases in postmenopausal women with early breast cancer. Oral bisphosphonate treatment could be sufficient for reducing the risk of bone metastases.
Source: Journal of Bone Oncology - Category: Cancer & Oncology Source Type: research
AbstractIt is not known whether increased breast cancer risk caused by menopausal hormone therapy (HT) depends on body mass patterns through life. In a prospective study of 483,241 Norwegian women aged 50 –69 years at baseline, 7656 women developed breast cancer during follow-up (2006–2013). We combined baseline information on recalled body mass in childhood/adolescence and current (baseline) body mass index (BMI) to construct mutually exclusive life-course body mass patterns. We assessed associ ations of current HT use with breast cancer risk according to baseline BMI and life-course patterns of body mass...
Source: European Journal of Epidemiology - Category: Epidemiology Source Type: research
AbstractThe improved detection and successful treatment of breast cancer, resulting in better survival rates, has led to an increasing number of women living with the effects of treatment modalities and their long-term consequences. Menopausal symptoms following breast cancer can occur at an earlier age, be more severe and significantly influence a woman ’s overall wellbeing, in particular, sexual function, quality of life and adherence to treatment. There is a dearth of good quality evidence on the safest and most effective treatment options available for these women, and this article aims to summarize the current a...
Source: Drugs and Aging - Category: Geriatrics Source Type: research
(Natural News) As the most common cancer among women around the world, breast cancer is one of the biggest health issues of our time. It’s also quite controversial, as you might expect, from a problem that has the potential to generate so many profits. In addition to living with a constant worry of developing this...
Source: NaturalNews.com - Category: Consumer Health News Source Type: news
Authors: Abderrahman B, Jordan VC Abstract The Women's Health Initiative (WHI) consisted of two placebo controlled trials: one in women with a uterus, using conjugated equine estrogen (CEE) plus medroxyprogesterone acetate (MPA) and the second trial in women without a uterus used CEE alone. The study population average age was approximately 63 years. Although the predicted rise in breast cancer occurred in the MPA plus CEE trial, the CEE alone trial, had a sustained decrease in breast cancer incidence. A unifying theory is presented that explains the decrease in breast cancer based on the new biology of estrog...
Source: Expert Review of Endocrinology and Metabolism - Category: Endocrinology Tags: Expert Rev Endocrinol Metab Source Type: research
Authors: Prince RM, Amir E Abstract In the last few years there have been significant advances in knowledge related to the treatment of post-menopausal women with early stage breast cancer. These include new information about the survival benefits with hormonal therapies and bone targeted treatments as well as identification of patient populations who may be able to avoid toxic treatments. In this paper we discuss these advances and provide suggested management algorithms. PMID: 30058935 [PubMed]
Source: Expert Review of Endocrinology and Metabolism - Category: Endocrinology Tags: Expert Rev Endocrinol Metab Source Type: research
More News: Breast Cancer | Canada Health | Cancer | Cancer & Oncology | Hormones | Men | Menopause | Study | Women